Tema ETFs LLC Invests $590,000 in Veeva Systems Inc. $VEEV

Tema ETFs LLC acquired a new position in shares of Veeva Systems Inc. (NYSE:VEEV) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,326 shares of the technology company’s stock, valued at approximately $590,000.

A number of other institutional investors have also recently bought and sold shares of the company. SHP Wealth Management acquired a new position in Veeva Systems in the 4th quarter worth about $26,000. Activest Wealth Management raised its stake in shares of Veeva Systems by 3,175.0% during the 4th quarter. Activest Wealth Management now owns 131 shares of the technology company’s stock worth $29,000 after purchasing an additional 127 shares in the last quarter. Arlington Trust Co LLC acquired a new stake in shares of Veeva Systems during the 2nd quarter valued at about $29,000. MV Capital Management Inc. acquired a new stake in shares of Veeva Systems during the 4th quarter valued at about $30,000. Finally, Reflection Asset Management bought a new stake in shares of Veeva Systems in the 4th quarter valued at approximately $32,000. Institutional investors and hedge funds own 88.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Piper Sandler dropped their price objective on Veeva Systems from $285.00 to $235.00 and set an “overweight” rating on the stock in a report on Thursday, June 4th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $275.00 target price on shares of Veeva Systems in a research note on Thursday, June 4th. Guggenheim initiated coverage on shares of Veeva Systems in a research report on Thursday, July 23rd. They issued a “buy” rating and a $232.00 target price for the company. The Goldman Sachs Group dropped their price target on shares of Veeva Systems from $190.00 to $165.00 and set a “sell” rating on the stock in a research note on Thursday, June 4th. Finally, BMO Capital Markets cut their price target on shares of Veeva Systems from $220.00 to $175.00 and set a “market perform” rating on the stock in a report on Thursday, June 4th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $247.08.

Veeva Systems Stock Down 3.6%

VEEV opened at $243.60 on Friday. The stock’s 50 day moving average price is $189.96 and its two-hundred day moving average price is $180.84. The firm has a market capitalization of $39.57 billion, a P/E ratio of 43.42, a price-to-earnings-growth ratio of 1.09 and a beta of 0.92. Veeva Systems Inc. has a 12-month low of $148.05 and a 12-month high of $310.50.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings results on Wednesday, June 3rd. The technology company reported $2.24 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. Veeva Systems had a return on equity of 13.72% and a net margin of 28.37%.The company had revenue of $882.95 million during the quarter, compared to analyst estimates of $857.73 million. During the same period in the previous year, the company earned $1.97 earnings per share. The company’s quarterly revenue was up 16.3% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 9.050-9.050 EPS and its Q2 2027 guidance at 2.210-2.220 EPS. As a group, analysts anticipate that Veeva Systems Inc. will post 6.65 earnings per share for the current year.

Veeva Systems Company Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.